HST Global, Inc. (HSTC)
USD 0.83
(0.0%)
USD 0.83
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 96.79 Thousand USD | 27.55% |
| 2022 | 75.88 Thousand USD | 38.35% |
| 2021 | 54.85 Thousand USD | 119.27% |
| 2020 | 25.01 Thousand USD | 1379.59% |
| 2019 | -1955.00 USD | -100.14% |
| 2018 | 1.37 Million USD | 1.78% |
| 2017 | 1.35 Million USD | 2.26% |
| 2016 | 1.32 Million USD | 1.69% |
| 2015 | 1.29 Million USD | 1.75% |
| 2014 | 1.27 Million USD | 2.17% |
| 2013 | 1.24 Million USD | 2.54% |
| 2012 | 1.21 Million USD | 12.9% |
| 2011 | 1.07 Million USD | 11.36% |
| 2010 | 969.44 Thousand USD | 229.02% |
| 2009 | 294.64 Thousand USD | 196.95% |
| 2008 | 99.22 Thousand USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 1.65 Million USD | 204.66% |
| 2005 | 542.83 Thousand USD | 166.2% |
| 2004 | 203.91 Thousand USD | 7.0% |
| 2003 | 190.58 Thousand USD | 229.02% |
| 2002 | -147.72 Thousand USD | -513.61% |
| 2001 | -24.07 Thousand USD | -220.37% |
| 2000 | 20 Thousand USD | 300.0% |
| 1999 | -10 Thousand USD | -102.33% |
| 1998 | 430 Thousand USD | -74.4% |
| 1997 | 1.68 Million USD | 5.0% |
| 1996 | 1.6 Million USD | -56.76% |
| 1995 | 3.7 Million USD | 42.31% |
| 1994 | 2.6 Million USD | 4.0% |
| 1993 | 2.5 Million USD | 150.0% |
| 1992 | 1 Million USD | 66.67% |
| 1991 | 600 Thousand USD | 500.0% |
| 1990 | 100 Thousand USD | 150.0% |
| 1989 | -200 Thousand USD | 71.43% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 16.44 Thousand USD | -83.47% |
| 2024 Q1 | 99.48 Thousand USD | 2.78% |
| 2023 Q3 | 91.31 Thousand USD | 5.02% |
| 2023 FY | 96.79 Thousand USD | 27.55% |
| 2023 Q2 | 86.95 Thousand USD | 3.56% |
| 2023 Q4 | 96.79 Thousand USD | 5.99% |
| 2023 Q1 | 83.96 Thousand USD | 10.64% |
| 2022 Q1 | 61.95 Thousand USD | 12.94% |
| 2022 Q4 | 75.88 Thousand USD | 6.43% |
| 2022 Q3 | 71.29 Thousand USD | 6.88% |
| 2022 Q2 | 66.71 Thousand USD | 7.69% |
| 2022 FY | 75.88 Thousand USD | 38.35% |
| 2021 Q1 | 31.09 Thousand USD | 24.31% |
| 2021 Q2 | 45.65 Thousand USD | 46.81% |
| 2021 FY | 54.85 Thousand USD | 119.27% |
| 2021 Q3 | 50.25 Thousand USD | 10.07% |
| 2021 Q4 | 54.85 Thousand USD | 9.15% |
| 2020 FY | 25.01 Thousand USD | 1379.59% |
| 2020 Q4 | 25.01 Thousand USD | 0.36% |
| 2020 Q1 | 5203.00 USD | 366.14% |
| 2020 Q2 | 20.2 Thousand USD | 288.33% |
| 2020 Q3 | 24.92 Thousand USD | 23.37% |
| 2019 FY | -1955.00 USD | -100.14% |
| 2019 Q1 | 1.37 Million USD | -1.5% |
| 2019 Q2 | 675 Thousand USD | -50.92% |
| 2019 Q3 | -16.95 Thousand USD | -102.51% |
| 2019 Q4 | -1955.00 USD | 88.47% |
| 2018 Q4 | 1.39 Million USD | 1.98% |
| 2018 FY | 1.37 Million USD | 1.78% |
| 2018 Q1 | 1.36 Million USD | 0.74% |
| 2018 Q2 | 1.36 Million USD | 0.32% |
| 2018 Q3 | 1.36 Million USD | 0.26% |
| 2017 Q1 | 1.32 Million USD | 0.62% |
| 2017 Q2 | 1.33 Million USD | 0.35% |
| 2017 Q3 | 1.34 Million USD | 0.75% |
| 2017 Q4 | 1.35 Million USD | 0.52% |
| 2017 FY | 1.35 Million USD | 2.26% |
| 2016 Q4 | 1.32 Million USD | 0.36% |
| 2016 Q2 | 1.31 Million USD | 1.04% |
| 2016 FY | 1.32 Million USD | 1.69% |
| 2016 Q1 | 1.29 Million USD | 0.01% |
| 2016 Q3 | 1.31 Million USD | 0.27% |
| 2015 Q1 | 1.28 Million USD | 0.68% |
| 2015 Q4 | 1.29 Million USD | 0.35% |
| 2015 FY | 1.29 Million USD | 1.75% |
| 2015 Q3 | 1.29 Million USD | 0.38% |
| 2015 Q2 | 1.28 Million USD | 0.33% |
| 2014 Q4 | 1.27 Million USD | 0.16% |
| 2014 Q1 | 1.25 Million USD | 0.74% |
| 2014 FY | 1.27 Million USD | 2.17% |
| 2014 Q3 | 1.27 Million USD | 0.54% |
| 2014 Q2 | 1.26 Million USD | 0.72% |
| 2013 Q3 | 1.24 Million USD | 0.81% |
| 2013 FY | 1.24 Million USD | 2.54% |
| 2013 Q4 | 1.24 Million USD | 0.08% |
| 2013 Q2 | 1.23 Million USD | 1.65% |
| 2013 Q1 | 1.21 Million USD | -0.01% |
| 2012 Q1 | 1.1 Million USD | -3.49% |
| 2012 Q4 | 1.21 Million USD | 4.28% |
| 2012 Q2 | 1.12 Million USD | 1.76% |
| 2012 FY | 1.21 Million USD | 12.9% |
| 2012 Q3 | 1.16 Million USD | 3.53% |
| 2011 FY | 1.07 Million USD | 11.36% |
| 2011 Q1 | 979.27 Thousand USD | 1.01% |
| 2011 Q2 | 1 Million USD | 3.09% |
| 2011 Q3 | 1.02 Million USD | 1.97% |
| 2011 Q4 | 1.14 Million USD | 11.66% |
| 2010 Q4 | 969.44 Thousand USD | 15.18% |
| 2010 FY | 969.44 Thousand USD | 229.02% |
| 2010 Q3 | 841.67 Thousand USD | 9.14% |
| 2010 Q2 | 771.15 Thousand USD | 16.54% |
| 2010 Q1 | 661.7 Thousand USD | 124.58% |
| 2009 Q2 | 257.6 Thousand USD | 43.11% |
| 2009 Q4 | 294.64 Thousand USD | 189.91% |
| 2009 FY | 294.64 Thousand USD | 196.95% |
| 2009 Q1 | 180 Thousand USD | 81.41% |
| 2009 Q3 | 101.63 Thousand USD | -60.55% |
| 2008 Q4 | 99.22 Thousand USD | 6.61% |
| 2008 FY | 99.22 Thousand USD | 0.0% |
| 2008 Q1 | 70 Thousand USD | 75.0% |
| 2008 Q2 | -178.58 Thousand USD | -355.13% |
| 2008 Q3 | 93.06 Thousand USD | 152.11% |
| 2007 Q2 | -644.00 USD | -100.03% |
| 2007 Q1 | 1.84 Million USD | 11.7% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | 40 Thousand USD | -50.0% |
| 2007 Q3 | 80 Thousand USD | 12522.36% |
| 2006 Q2 | 1.92 Million USD | 959.62% |
| 2006 Q1 | 181.38 Thousand USD | -76.83% |
| 2006 Q4 | 1.65 Million USD | -22.11% |
| 2006 FY | 1.65 Million USD | 204.66% |
| 2006 Q3 | 2.12 Million USD | 10.48% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | 542.83 Thousand USD | 166.2% |
| 2005 Q1 | 221.52 Thousand USD | 8.63% |
| 2005 Q2 | 222.6 Thousand USD | 0.49% |
| 2005 Q4 | 782.83 Thousand USD | 0.0% |
| 2004 Q4 | 203.91 Thousand USD | -2.54% |
| 2004 Q2 | 233.5 Thousand USD | -0.63% |
| 2004 Q1 | 234.97 Thousand USD | 23.29% |
| 2004 Q3 | 209.22 Thousand USD | -10.4% |
| 2004 FY | 203.91 Thousand USD | 7.0% |
| 2003 Q4 | 190.58 Thousand USD | -4.71% |
| 2003 Q1 | - USD | 100.0% |
| 2003 FY | 190.58 Thousand USD | 229.02% |
| 2003 Q3 | 200 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | -147.72 Thousand USD | -513.61% |
| 2002 Q1 | 6659.00 USD | 166.59% |
| 2002 Q2 | -62.00 USD | -100.93% |
| 2002 Q3 | -62.00 USD | 0.0% |
| 2002 Q4 | -37.72 Thousand USD | -60738.71% |
| 2001 Q4 | -10 Thousand USD | -103.33% |
| 2001 FY | -24.07 Thousand USD | -220.37% |
| 2001 Q1 | 380 Thousand USD | 0.0% |
| 2001 Q2 | 340 Thousand USD | -10.53% |
| 2001 Q3 | 300 Thousand USD | -11.76% |
| 2000 Q1 | 120 Thousand USD | 1300.0% |
| 2000 Q4 | 380 Thousand USD | -22.45% |
| 2000 Q3 | 490 Thousand USD | 53.13% |
| 2000 Q2 | 320 Thousand USD | 166.67% |
| 2000 FY | 20 Thousand USD | 300.0% |
| 1999 Q4 | -10 Thousand USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | -10 Thousand USD | -102.33% |
| 1999 Q1 | -30 Thousand USD | -160.0% |
| 1999 Q2 | - USD | 100.0% |
| 1998 Q2 | 420 Thousand USD | -75.29% |
| 1998 Q3 | 780 Thousand USD | 85.71% |
| 1998 Q1 | 1.7 Million USD | 1.19% |
| 1998 Q4 | 50 Thousand USD | -93.59% |
| 1998 FY | 430 Thousand USD | -74.4% |
| 1997 Q2 | 1.96 Million USD | 22.5% |
| 1997 Q3 | 1.99 Million USD | 1.53% |
| 1997 Q4 | 1.68 Million USD | -15.58% |
| 1997 FY | 1.68 Million USD | 5.0% |
| 1997 Q1 | 1.6 Million USD | 0.0% |
| 1996 FY | 1.6 Million USD | -56.76% |
| 1996 Q1 | 3.5 Million USD | -5.41% |
| 1996 Q2 | 3.5 Million USD | 0.0% |
| 1996 Q3 | 1.5 Million USD | -57.14% |
| 1996 Q4 | 1.6 Million USD | 6.67% |
| 1995 Q4 | 3.7 Million USD | 12.12% |
| 1995 Q1 | 2.7 Million USD | 3.85% |
| 1995 Q2 | 2.9 Million USD | 7.41% |
| 1995 Q3 | 3.3 Million USD | 13.79% |
| 1995 FY | 3.7 Million USD | 42.31% |
| 1994 Q4 | 2.6 Million USD | -3.7% |
| 1994 Q1 | 2.6 Million USD | 4.0% |
| 1994 Q2 | 2.1 Million USD | -19.23% |
| 1994 Q3 | 2.7 Million USD | 28.57% |
| 1994 FY | 2.6 Million USD | 4.0% |
| 1993 Q1 | 1 Million USD | 0.0% |
| 1993 Q2 | 1.1 Million USD | 10.0% |
| 1993 FY | 2.5 Million USD | 150.0% |
| 1993 Q3 | 1.1 Million USD | 0.0% |
| 1993 Q4 | 2.5 Million USD | 127.27% |
| 1992 FY | 1 Million USD | 66.67% |
| 1992 Q1 | 600 Thousand USD | 0.0% |
| 1992 Q2 | 800 Thousand USD | 33.33% |
| 1992 Q3 | 900 Thousand USD | 12.5% |
| 1992 Q4 | 1 Million USD | 11.11% |
| 1991 Q2 | - USD | -100.0% |
| 1991 Q4 | 600 Thousand USD | 100.0% |
| 1991 FY | 600 Thousand USD | 500.0% |
| 1991 Q1 | 100 Thousand USD | 0.0% |
| 1991 Q3 | 300 Thousand USD | 0.0% |
| 1990 Q3 | 300 Thousand USD | 0.0% |
| 1990 FY | 100 Thousand USD | 150.0% |
| 1990 Q4 | 100 Thousand USD | -66.67% |
| 1990 Q1 | 300 Thousand USD | 250.0% |
| 1990 Q2 | 300 Thousand USD | 0.0% |
| 1989 Q2 | -300 Thousand USD | 0.0% |
| 1989 Q4 | -200 Thousand USD | 33.33% |
| 1989 FY | -200 Thousand USD | 71.43% |
| 1989 Q3 | -300 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 7488.779% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 98.286% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.774% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 138.776% |
| Rebus Holdings, Inc. | 305 Thousand USD | 68.265% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 101.535% |
| Qrons Inc. | 351.42 Thousand USD | 72.457% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 84.448% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.777% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 574.289% |
| Skye Bioscience, Inc. | -5.72 Million USD | 101.692% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.386% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 97.65% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 75.913% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.267% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 95.683% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 89.561% |
| Mesoblast Limited | 55.85 Million USD | 99.827% |
| Marizyme, Inc. | 18.56 Million USD | 99.479% |
| Genus plc | 190.6 Million USD | 99.949% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 95.671% |
| Pharming Group N.V. | 109.8 Million USD | 99.912% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 88.748% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 92.026% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 85.766% |
| ContraFect Corporation | -6.02 Million USD | 101.606% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 28.109% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 91.623% |
| IMV Inc. | 7.67 Million USD | 98.738% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 98.241% |
| MultiCell Technologies, Inc. | 90.04 USD | -107400.0% |
| ONE Bio Corp. | 9.04 Million USD | 98.929% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 113.187% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 99.252% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 92.924% |
| Q BioMed Inc. | 4.06 Million USD | 97.616% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.683% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 90.395% |
| Biomind Labs Inc. | 711.4 Thousand USD | 86.394% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.84% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 95.159% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 99.244% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 73.091% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 30.765% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -387.205% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 95.604% |
| GB Sciences, Inc. | 1.74 Million USD | 94.46% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 152.666% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 53.063% |
| Halberd Corporation | 144.72 Thousand USD | 33.118% |
| Enzolytics Inc. | 981.65 Thousand USD | 90.14% |
| Agentix Corp. | 37.63 Thousand USD | -157.216% |
| Resverlogix Corp. | 6.45 Million USD | 98.5% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 114.38% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.005% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.206% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.631% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 96.426% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 101.095% |
| AVAX Technologies, Inc. | -5.9 Million USD | 101.64% |
| Zenith Capital Corp. | 10.06 Thousand USD | -861.775% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.009% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 51.708% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 95.943% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 41.162% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 628.404% |
| Kadimastem Ltd | -253.1 Thousand USD | 138.243% |
| Helix BioMedix, Inc. | -2.57 Million USD | 103.766% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.523% |
| BioStem Technologies, Inc. | 4.47 Million USD | 97.836% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 51.905% |
| LadRx Corporation | -2.03 Million USD | 104.753% |
| Cell Source, Inc. | 9.23 Million USD | 98.952% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 84.761% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 84.761% |
| NovAccess Global Inc. | 2.17 Million USD | 95.557% |
| Affymax, Inc. | -5.59 Million USD | 101.729% |
| Itoco Inc. | 228.3 Thousand USD | 57.604% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 28.823% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 98.047% |
| Mobile Lads Corp. | 484.23 Thousand USD | 80.011% |
| CytoDyn Inc. | 20.26 Million USD | 99.522% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 15060.278% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1144.34% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.744% |
| SYBLEU INC | 473.71 Thousand USD | 79.567% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 97.828% |
| International Stem Cell Corporation | 2.59 Million USD | 96.263% |
| Bioxytran, Inc. | 1.89 Million USD | 94.903% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -55.085% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 95.562% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 97.181% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.868% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 87.472% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 107.743% |
| Neutra Corp. | 52.18 Thousand USD | -85.473% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 103.889% |
| PureTech Health plc | -167.19 Million USD | 100.058% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 139.522% |
| IXICO plc | -4.44 Million USD | 102.178% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 99.268% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.824% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.221% |